Trevi Therapeutics Inc. (NASDAQ:TRVI) is one of the best multibagger stocks to invest in right now. On August 21, Morgan Stanley’s Judah Frommer initiated coverage of the stock with an Overweight rating and an $18 price target. The Overweight call is based on Haduvio, the company’s extended-release formulation of nalbuphine, which is being developed as a treatment for chronic cough.
Frommer said Haduvio stands out in a market where existing therapies either offer limited benefit or pose risks such as abuse and respiratory complications. He highlighted its potential to meet a large unmet need for patients with persistent cough.
The analyst estimates that Haduvio could become a multi-billion-dollar opportunity for Trevi Therapeutics Inc., with growing interest in the pharmaceutical industry adding further support. Large-cap peers such as GSK and Merck have already committed to billion-dollar partnerships in the chronic cough space, suggesting Trevi Therapeutics Inc. could benefit from heightened attention and investment.
Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company developing Haduvio to help patients suffering from chronic cough.
READ NEXT: 10 Most Shorted Stocks Right Now and 10 Best High Beta Stocks To Buy Now.
This article is originally published at Insider Monkey.
